← Back to headlines
Johnson & Johnson Acquires Option for Sail in vivo CAR-T Therapies
Johnson & Johnson has secured a $2.58 billion option to acquire Sail's in vivo CAR-T therapies. This strategic move aims to bolster Johnson & Johnson's presence in the rapidly evolving field of cell-based cancer treatments.
29 Jul, 21:49 — 29 Jul, 21:49
Sources
Showing 1 of 1 sources
